Posted by Michael Wonder on 29 Aug 2018
Life-changing drug Spinraza for spinal muscular atrophy patients costing adults at least $500,000
29 August 2018 - In a small lounge in Essendon, with his parents by his side, Chris Kessaris sat in his wheelchair and watched as the Federal Government told him on television that he would never be free of it.
Mr Kessaris, 25, suffers from type 2 spinal muscular atrophy, or SMA, and has been confined to a wheelchair since grade 1.
The government announced in May that a potentially life-changing drug — Spinraza — would be included on the pharmaceutical benefits scheme only for people under the age of 18.
